Article Text

Download PDFPDF
Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial
  1. P L C M van Riel1,
  2. B Freundlich2,
  3. D MacPeek2,
  4. R Pedersen2,
  5. J R Foehl2,
  6. A Singh2,
  7. on behalf of ADORE study investigators
  1. 1
    Department of Rheumatology Radboud University, Nijmegen Medical Center, Nijmegen, the Netherlands
  2. 2
    Wyeth Research, Collegeville, Philadelphia, USA
  1. A Singh, PhD, Global Health Outcomes Assessment, Wyeth Research, Collegeville, PA 19426, USA; singha2{at}


Objectives: This study assessed the relative efficacy of etanercept (ETN) or etanercept and methotrexate (ETN+MTX) for patients with rheumatoid arthritis (RA) who had an unsatisfactory response to MTX, using patient-reported outcomes (PROs) of function, pain, general health, disease activity and morning stiffness.

Methods: The PROs were secondary assessments in a 16-week, prospective, randomised, parallel-group study conducted at 60 European centres. Patients with RA were randomly assigned either to monotherapy with ETN or combination therapy with ETN+MTX. PRO instruments administered included the Stanford Health Assessment Questionnaire, the pain visual analogue scale, the EuroQoL assessment of current health state (EQ-5D), the EQ-5D visual analogue scale, a patient global assessment of disease activity and an assessment of morning stiffness. Treatment groups were compared by percentage of patients within clinically meaningful categories. The primary endpoint for all PROs was comparison of mean improvement from baseline to week 16 between ETN and ETN+MTX groups.

Results: Three hundred and fifteen patients were randomised to ETN or ETN+MTX. Both treatment arms had similar Health Assessment Questionnaire Disability Index DI, EQ-5D, patient global assessment of disease activity, pain or morning stiffness scores and improvement from baseline to week 16.

Conclusions: For patients with active RA and intolerance or unsatisfactory response to MTX, substituting ETN for MTX and adding ETN to MTX are both effective ways of reducing disability, pain, disease activity, morning stiffness, and improving general health.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: This study was made possible by a grant from Wyeth Pharmaceuticals Inc. The study was Wyeth’s own protocol. The study design, data collection, analysis and interpretation and writing of the report were done by Wyeth Research.

  • Competing interests: AS, DM, RP and BF are employees of Wyeth and hold stock and/or stock options in Wyeth.